<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fesoterodine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fesoterodine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fesoterodine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12175" href="/d/html/12175.html" rel="external">see "Fesoterodine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="132467" href="/d/html/132467.html" rel="external">see "Fesoterodine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6788469"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Toviaz</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397500"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>SANDOZ Fesoterodine Fumarate;</li>
<li>Toviaz</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6821328"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F6821362"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b>
<b>Oral:</b> 4 mg once daily; may be increased to a maximum dose of 8 mg once daily based on individual response and tolerability</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991098"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Maximum dose: 4 mg once daily</p></div>
<div class="block doha drugH1Div" id="F50988384"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.</p></div>
<div class="block doe drugH1Div" id="F6821363"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F56099799"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="132467" href="/d/html/132467.html" rel="external">see "Fesoterodine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Toviaz is an extended-release dosage form; patients must be able to swallow tablets whole.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cfba3c5-bb68-46a2-9ab8-73ec41e1d445">Neurogenic detrusor overactivity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity (NDO):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;25 kg to ≤35 kg: Oral: 4 mg once daily; may be increased to 8 mg once daily based on individual response and tolerability; in patients &gt;35 kg, doses were titrated after ≥1 week of therapy; maximum daily dose: 8 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;35 kg: Oral: Initial: 4 mg once daily; after 1 week of therapy, increase dose to 8 mg once daily; maximum daily dose: 8 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56099800"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pediatric dosing recommendations are based on extrapolation of adult data and assumption of similar proportional renal elimination.</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;25 kg to ≤35 kg: Maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;35 kg: Initial dose: No dosage adjustment needed; maximum daily dose: 8 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;25 kg to ≤35 kg: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;35 kg: Maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: All pediatric patients: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: All pediatric patients: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F56099801"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.</p></div>
<div class="block adr drugH1Div" id="F6821339"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are reported for overactive bladder (OAB) unless otherwise noted as neurogenic detrusor overactivity (NDO).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (NDO: 7% to 12%), xerostomia (NDO: 7% to 10%; OAB: 19% to 35%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (1%), weight gain (NDO: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (NDO: 5% to 7%; OAB: 1%), constipation (NDO: 7%; OAB: 4% to 6%), dyspepsia (2%), nausea (NDO: 2% to 5%; OAB: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (1% to 2%), urinary retention (1%), urinary tract infection (NDO: 2% to 10%; OAB: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (NDO: 5% to 7%), insomnia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance (NDO: ≤6%), blurred vision (NDO: ≤6%), dry eye syndrome (1% to 4%), myopia (NDO: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2%), dry throat (2%), upper respiratory tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: <b></b>Angina pectoris, chest pain, prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal<b>: </b>Decreased gastrointestinal motility, diverticulitis of the gastrointestinal tract, gastroenteritis, irritable bowel syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any indication): Cardiovascular: Increased heart rate</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial edema, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness</p></div>
<div class="block coi drugH1Div" id="F6821335"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, angioedema) to fesoterodine, tolterodine, or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma.</p></div>
<div class="block war drugH1Div" id="F6821336"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported; may be life-threatening. Cases may occur after the initial dose or after multiple doses. Discontinue immediately if tongue, hypopharynx, or larynx are involved.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Anticholinergics may cause drowsiness, dizziness, headache, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder flow obstruction: Use is not recommended in patients with significant bladder outlet obstruction; may increase the risk of urinary retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI obstructive disorders: Use is not recommended in patients with decreased GI motility (eg, severe constipation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment; has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dose adjustment recommended in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Risk of adverse effects may be increased in older adult patients.</p></div>
<div class="block foc drugH1Div" id="F6821368"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toviaz: 4 mg, 8 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block geq drugH1Div" id="F6821326"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16321860"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Fesoterodine Fumarate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $13.41 - $13.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $13.41 - $13.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Toviaz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $11.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $11.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397501"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toviaz: 4 mg, 8 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block adm drugH1Div" id="F6821366"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food. Swallow whole; do not chew, crush, or divide.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation is available. Consider switching to tolterodine immediate release, since both fesoterodine and tolterodine are metabolized to the same active drug.</p></div>
<div class="block admp drugH1Div" id="F56099802"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered with or without food. Swallow whole; do not chew, crush, or divide.</p></div>
<div class="block use drugH1Div" id="F6821330"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity: </b>Treatment of neurogenic detrusor overactivity in pediatric patients ≥6 years of age and weighing &gt;25 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b> Treatment of overactive bladder in adults with symptoms of urinary frequency, urgency, or urge incontinence.</p></div>
<div class="block mst drugH1Div" id="F6821325"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fesoterodine may be confused with fexofenadine, tolterodine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Adult Older: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Fesoterodine is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299329"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6833846"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Fesoterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Fesoterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Fesoterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Fesoterodine. Management: Limit fesoterodine doses to 4 mg daily in patients who are also receiving strong CYP3A4 inhibitors. This combination is not recommended in pediatric patients weighing 25 kg up to 35 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase serum concentrations of the active metabolite(s) of Fesoterodine. Management: Limit fesoterodine doses to 4 mg daily when combined with itraconazole. Use of fesoterodine with itraconazole, or for 2 weeks after itraconazole discontinuation, in patients with moderate to severe hepatic or renal impairment is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: May enhance the adverse/toxic effect of Fesoterodine. Mirabegron may increase serum concentrations of the active metabolite(s) of Fesoterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F6821332"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects have been observed in some animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F16355062"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if fesoterodine is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F50293170"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Anticholinergic effects (ie, dry mouth, constipation, dizziness); renal function; hepatic function; postvoid residual urine volume at baseline and as clinically indicated thereafter (AUA [Lerner 2021]); urinary tract infection prior to initiation of therapy (ACOG 2015).</p></div>
<div class="block pha drugH1Div" id="F6821347"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fesoterodine acts as a prodrug and is converted to an active metabolite, 5-hydroxymethyl tolterodine (5-HMT); 5-HMT is responsible for fesoterodine’s antimuscarinic activity and acts as a competitive antagonist of muscarinic receptors.</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Urinary bladder contractions are mediated by muscarinic receptors; fesoterodine inhibits the receptors in the bladder preventing symptoms of urgency and frequency.</p></div>
<div class="block phk drugH1Div" id="F6821349"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 5-HMT:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): Oral: 68 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: V<sub>d</sub>: 169 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 5-HMT: ~50% (primarily to albumin and alpha<sub>1</sub>-acid glycoprotein).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Fesoterodine is rapidly and extensively metabolized to its active metabolite (5-hydroxymethyl tolterodine; 5-HMT) by nonspecific esterases; 5-HMT is further metabolized via CYP2D6 and CYP3A4 to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 5-HMT: 52%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): 7.73 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 5-HMT: C<sub>max</sub> ~2-fold higher in poor CYP2D6 metabolizers.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years (weighing ≥35 kg): 2.55 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Median: ~5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~70%; 16% as 5-HMT, ~53% as inactive metabolites); feces (7%).</p></div>
<div class="block phksp drugH1Div" id="F51192550"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Plasma concentrations of the active metabolite are increased in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma concentrations of the active metabolite are increased in patients with hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992807"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodine aristo | Toviaz</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodina alter | Fesoterodina aristo | Fesoterodina aurovitas | Fesoterodina cinfa | Fesoterodina normon | Fesoterodina stada | Toviaz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodine arrow | Fesoterodine biogaran | Fesoterodine teva | Fesoterodine zentiva | Toviaz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodine fumarate aristo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodine clonmel | Fesoterodine pinewood | Toviaz</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fesobig</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodine accord | Fesoterodine aristo | Fesoterodine CF | Fesoterodine teva | Fesoterodine xiromed | Toviaz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fesoterodin Accord | Toviaz</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Toviaz</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26488524">
<a name="26488524"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. <i>Obstet Gynecol</i>. 2015;126(5):e66-e81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/26488524/pubmed" id="26488524" target="_blank">26488524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17651893">
<a name="17651893"></a>Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [published correction appears in: <i>Eur Urol</i>. 2008;53(6):1319]. <i>Eur Urol</i>. 2007;52(4):1204-1212. doi: 10.1016/j.eururo.2007.07.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/17651893/pubmed" id="17651893" target="_blank">17651893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18342923">
<a name="18342923"></a>Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome [published correction appears in: <i>Urology</i>. 2009;74(3):716]. <i>Urology</i>. 2008;71(5):839-843. doi: 10.1016/j.urology.2007.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/18342923/pubmed" id="18342923" target="_blank">18342923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18570610">
<a name="18570610"></a>Michel M. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. <i>Expert Opin Pharmacother.</i> 2008;9(10):1787-1796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/18570610/pubmed" id="18570610" target="_blank">18570610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17937959">
<a name="17937959"></a>Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. <i>J Urol.</i> 2007;178(5):2488-2494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fesoterodine-drug-information/abstract-text/17937959/pubmed" id="17937959" target="_blank">17937959</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Toviaz (fesoterodine) [prescribing information]. New York, NY: Pfizer Inc; November 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9061 Version 329.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
